Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Using Census Data to Understand County-Level Differences in Overall Drug Mortality and Opioid-Related Mortality by Opioid Type.

Monnat SM, Peters DJ, Berg MT, Hochstetler A.

Am J Public Health. 2019 Jun 20:e1-e8. doi: 10.2105/AJPH.2019.305136. [Epub ahead of print]

PMID:
31219718
2.

IN VITRO 3D PHENOTYPIC DRUG SCREEN IDENTIFIES CELASTROL AS AN EFFECTIVE IN VIVO INHIBITOR OF POLYCYSTIC KIDNEY DISEASE.

Booij TH, Leonhard WN, Bange H, Yan K, Fokkelman M, Plugge AJ, Veraar KAM, Dauwerse JG, van Westen GJP, van de Water B, Price LS, Peters DJM.

J Mol Cell Biol. 2019 May 8. pii: mjz029. doi: 10.1093/jmcb/mjz029. [Epub ahead of print]

PMID:
31065693
3.

Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury.

Formica C, Happé H, Veraar KA, Vortkamp A, Scharpfenecker M, McNeill H, Peters DJ.

J Pathol. 2019 Apr 30. doi: 10.1002/path.5286. [Epub ahead of print]

PMID:
31038742
4.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators.

Gastroenterology. 2019 Apr 22. pii: S0016-5085(19)36711-3. doi: 10.1053/j.gastro.2019.04.018. [Epub ahead of print]

PMID:
31022403
5.

Drug prioritization using the semantic properties of a knowledge graph.

Malas TB, Vlietstra WJ, Kudrin R, Starikov S, Charrout M, Roos M, Peters DJM, Kors JA, Vos R, 't Hoen PAC, van Mulligen EM, Hettne KM.

Sci Rep. 2019 Apr 18;9(1):6281. doi: 10.1038/s41598-019-42806-6.

6.

Sheathless CE-MS based metabolic profiling of kidney tissue section samples from a mouse model of Polycystic Kidney Disease.

Sánchez-López E, Kammeijer GSM, Crego AL, Marina ML, Ramautar R, Peters DJM, Mayboroda OA.

Sci Rep. 2019 Jan 28;9(1):806. doi: 10.1038/s41598-018-37512-8.

7.

Tubular flow activates magnesium transport in the distal convoluted tubule.

Verschuren EHJ, Hoenderop JGJ, Peters DJM, Arjona FJ, Bindels RJM.

FASEB J. 2019 Apr;33(4):5034-5044. doi: 10.1096/fj.201802094R. Epub 2018 Dec 31.

PMID:
30596515
8.

Polycystic kidney disease.

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE.

Nat Rev Dis Primers. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. Review.

PMID:
30523303
9.

Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.

Shi H, Leonhard WN, Sijbrandi NJ, van Steenbergen MJ, Fens MHAM, van de Dikkenberg JB, Toraño JS, Peters DJM, Hennink WE, Kok RJ.

J Control Release. 2019 Jan 10;293:113-125. doi: 10.1016/j.jconrel.2018.11.019. Epub 2018 Nov 23.

10.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators.

JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.

11.

Comparative transcriptomics of shear stress treated Pkd1-/- cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease.

Kunnen SJ, Malas TB, Formica C, Leonhard WN, 't Hoen PAC, Peters DJM.

Biomed Pharmacother. 2018 Dec;108:1123-1134. doi: 10.1016/j.biopha.2018.07.178. Epub 2018 Oct 1.

12.

The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.

Lin C, Happé H, Veraar K, Scharpfenecker M, Peters DJ; Dipak Consortium.

Exp Biol Med (Maywood). 2018 Sep;243(13):1092-1098. doi: 10.1177/1535370218803893. Epub 2018 Sep 27.

PMID:
30261745
13.

HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease.

Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, Kunzelmann K, Eckardt KU, Buchholz B.

Kidney Int. 2018 Nov;94(5):887-899. doi: 10.1016/j.kint.2018.06.008. Epub 2018 Aug 30.

PMID:
30173898
14.

Targeted deletion of the AAA-ATPase Ruvbl1 in mice disrupts ciliary integrity and causes renal disease and hydrocephalus.

Dafinger C, Rinschen MM, Borgal L, Ehrenberg C, Basten SG, Franke M, Höhne M, Rauh M, Göbel H, Bloch W, Wunderlich FT, Peters DJM, Tasche D, Mishra T, Habbig S, Dötsch J, Müller RU, Brüning JC, Persigehl T, Giles RH, Benzing T, Schermer B, Liebau MC.

Exp Mol Med. 2018 Jun 28;50(6):75. doi: 10.1038/s12276-018-0108-z.

15.

Polycystin-1 dysfunction impairs electrolyte and water handling in a renal precystic mouse model for ADPKD.

Verschuren EHJ, Mohammed SG, Leonhard WN, Overmars-Bos C, Veraar K, Hoenderop JGJ, Bindels RJM, Peters DJM, Arjona FJ.

Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F537-F546. doi: 10.1152/ajprenal.00622.2017. Epub 2018 May 16.

PMID:
29767557
16.

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.

Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT; DIPAK Consortium.

Kidney Int Rep. 2017 Oct 14;3(2):291-301. doi: 10.1016/j.ekir.2017.10.004. eCollection 2018 Mar.

17.

Comprehensive transcriptome analysis of fluid shear stress altered gene expression in renal epithelial cells.

Kunnen SJ, Malas TB, Semeins CM, Bakker AD, Peters DJM.

J Cell Physiol. 2018 Apr;233(4):3615-3628. doi: 10.1002/jcp.26222. Epub 2017 Nov 20.

18.

The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.

D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH.

Am J Nephrol. 2017;46(3):239-248. doi: 10.1159/000479436. Epub 2017 Sep 8.

PMID:
28881341
19.

A cross-platform metabolomics workflow for volume-restricted tissue samples: application to an animal model for polycystic kidney disease.

Sánchez-López E, Happé H, Steenvoorden E, Crego AL, Marina ML, Peters DJM, Mayboroda OA.

Mol Biosyst. 2017 Sep 26;13(10):1940-1945. doi: 10.1039/c7mb00245a.

PMID:
28820206
20.

High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.

Booij TH, Bange H, Leonhard WN, Yan K, Fokkelman M, Kunnen SJ, Dauwerse JG, Qin Y, van de Water B, van Westen GJP, Peters DJM, Price LS.

SLAS Discov. 2017 Sep;22(8):974-984. doi: 10.1177/2472555217716056. Epub 2017 Jun 23.

21.

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.

Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, Felsher DW, Walter V, Zhang Q, Parker JS, Yeh JJ, Moffitt RA, Leung JY, Kim WY.

Nat Commun. 2017 Jun 8;8:15770. doi: 10.1038/ncomms15770.

22.

Detecting PKD1 variants in polycystic kidney disease patients by single-molecule long-read sequencing.

Borràs DM, Vossen RHAM, Liem M, Buermans HPJ, Dauwerse H, van Heusden D, Gansevoort RT, den Dunnen JT, Janssen B, Peters DJM, Losekoot M, Anvar SY.

Hum Mutat. 2017 Jul;38(7):870-879. doi: 10.1002/humu.23223. Epub 2017 May 29.

23.

Fluid shear stress-induced TGF-β/ALK5 signaling in renal epithelial cells is modulated by MEK1/2.

Kunnen SJ, Leonhard WN, Semeins C, Hawinkels LJAC, Poelma C, Ten Dijke P, Bakker A, Hierck BP, Peters DJM.

Cell Mol Life Sci. 2017 Jun;74(12):2283-2298. doi: 10.1007/s00018-017-2460-x. Epub 2017 Feb 6.

24.

Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes.

Malas TB, Formica C, Leonhard WN, Rao P, Granchi Z, Roos M, Peters DJ, 't Hoen PA.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F806-F817. doi: 10.1152/ajprenal.00653.2016. Epub 2017 Feb 1. Erratum in: Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F140.

25.

STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.

Fragiadaki M, Lannoy M, Themanns M, Maurer B, Leonhard WN, Peters DJ, Moriggl R, Ong AC.

Kidney Int. 2017 Mar;91(3):575-586. doi: 10.1016/j.kint.2016.10.039. Epub 2017 Jan 16.

26.

Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.

Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, Harris PC, Peters DJ, Ong AC.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F577-F588. doi: 10.1152/ajprenal.00607.2016. Epub 2017 Jan 11.

27.

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT; DIPAK Consortium.

Drug Saf. 2017 Feb;40(2):153-167. doi: 10.1007/s40264-016-0486-x.

28.

Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling.

Calcagnì A, Kors L, Verschuren E, De Cegli R, Zampelli N, Nusco E, Confalonieri S, Bertalot G, Pece S, Settembre C, Malouf GG, Leemans JC, de Heer E, Salvatore M, Peters DJ, Di Fiore PP, Ballabio A.

Elife. 2016 Sep 26;5. pii: e17047. doi: 10.7554/eLife.17047.

29.

Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.

Fergelot P, Van Belzen M, Van Gils J, Afenjar A, Armour CM, Arveiler B, Beets L, Burglen L, Busa T, Collet M, Deforges J, de Vries BB, Dominguez Garrido E, Dorison N, Dupont J, Francannet C, Garciá-Minaúr S, Gabau Vila E, Gebre-Medhin S, Gener Querol B, Geneviève D, Gérard M, Gervasini CG, Goldenberg A, Josifova D, Lachlan K, Maas S, Maranda B, Moilanen JS, Nordgren A, Parent P, Rankin J, Reardon W, Rio M, Roume J, Shaw A, Smigiel R, Sojo A, Solomon B, Stembalska A, Stumpel C, Suarez F, Terhal P, Thomas S, Touraine R, Verloes A, Vincent-Delorme C, Wincent J, Peters DJ, Bartsch O, Larizza L, Lacombe D, Hennekam RC.

Am J Med Genet A. 2016 Dec;170(12):3069-3082. doi: 10.1002/ajmg.a.37940. Epub 2016 Sep 20.

PMID:
27648933
30.

Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Zittema D, Versteeg IB, Gansevoort RT, van Goor H, de Heer E, Veraar KA, Peters DJ, Meijer E.

Am J Nephrol. 2016;44(3):194-203. doi: 10.1159/000448693. Epub 2016 Aug 31.

31.

P2Y2R is a direct target of HIF-1α and mediates secretion-dependent cyst growth of renal cyst-forming epithelial cells.

Kraus A, Grampp S, Goppelt-Struebe M, Schreiber R, Kunzelmann K, Peters DJ, Leipziger J, Schley G, Schödel J, Eckardt KU, Buchholz B.

Purinergic Signal. 2016 Dec;12(4):687-695. Epub 2016 Aug 26.

32.

Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Leonhard WN, Happe H, Peters DJ.

J Am Soc Nephrol. 2016 Dec;27(12):3530-3538. Epub 2016 Aug 4. Review.

33.

CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype.

Menke LA, van Belzen MJ, Alders M, Cristofoli F; DDD Study, Ehmke N, Fergelot P, Foster A, Gerkes EH, Hoffer MJ, Horn D, Kant SG, Lacombe D, Leon E, Maas SM, Melis D, Muto V, Park SM, Peeters H, Peters DJ, Pfundt R, van Ravenswaaij-Arts CM, Tartaglia M, Hennekam RC.

Am J Med Genet A. 2016 Oct;170(10):2681-93. doi: 10.1002/ajmg.a.37800. Epub 2016 Jun 17.

PMID:
27311832
34.

Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease.

Leonhard WN, Kunnen SJ, Plugge AJ, Pasternack A, Jianu SB, Veraar K, El Bouazzaoui F, Hoogaars WM, Ten Dijke P, Breuning MH, De Heer E, Ritvos O, Peters DJ.

J Am Soc Nephrol. 2016 Dec;27(12):3589-3599. Epub 2016 Mar 28.

35.

Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease.

Salih M, Demmers JA, Bezstarosti K, Leonhard WN, Losekoot M, van Kooten C, Gansevoort RT, Peters DJ, Zietse R, Hoorn EJ; DIPAK Consortium.

J Am Soc Nephrol. 2016 Oct;27(10):3079-3092. Epub 2016 Mar 3.

36.

Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept.

Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H, Haffner C, van Ommen GJ, Aartsma-Rus AM, Lesnik Oberstein SA.

Brain. 2016 Apr;139(Pt 4):1123-35. doi: 10.1093/brain/aww011. Epub 2016 Feb 19.

PMID:
26912635
37.

Is the Anterior Approach Safe? Early Complication Rate Associated With 5090 Consecutive Primary Total Hip Arthroplasty Procedures Performed Using the Anterior Approach.

Barnett SL, Peters DJ, Hamilton WG, Ziran NM, Gorab RS, Matta JM.

J Arthroplasty. 2016 Oct;31(10):2291-4. doi: 10.1016/j.arth.2015.07.008. Epub 2015 Jul 11.

PMID:
26897487
38.

Glucose promotes secretion-dependent renal cyst growth.

Kraus A, Schley G, Kunzelmann K, Schreiber R, Peters DJ, Stadler R, Eckardt KU, Buchholz B.

J Mol Med (Berl). 2016 Jan;94(1):107-17. doi: 10.1007/s00109-015-1337-4. Epub 2015 Sep 3.

PMID:
26334260
39.

Estimation of total kidney volume in autosomal dominant polycystic kidney disease.

Spithoven EM, van Gastel MD, Messchendorp AL, Casteleijn NF, Drenth JP, Gaillard CA, de Fijter JW, Meijer E, Peters DJ, Kappert P, Renken RJ, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium; DIPAK Consortium.

Am J Kidney Dis. 2015 Nov;66(5):792-801. doi: 10.1053/j.ajkd.2015.06.017. Epub 2015 Jul 31.

PMID:
26235803
40.

Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases.

Huang JL, Woolf AS, Kolatsi-Joannou M, Baluk P, Sandford RN, Peters DJ, McDonald DM, Price KL, Winyard PJ, Long DA.

J Am Soc Nephrol. 2016 Jan;27(1):69-77. doi: 10.1681/ASN.2014090856. Epub 2015 Jun 2.

41.

Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.

Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X.

J Clin Invest. 2015 Jun;125(6):2399-412. doi: 10.1172/JCI80467. Epub 2015 May 11.

42.

The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.

Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, Walz G, Zhou J, Yu AS.

J Am Soc Nephrol. 2015 Sep;26(9):2081-95. doi: 10.1681/ASN.2014121192. Epub 2015 May 7.

43.

LRP5 variants may contribute to ADPKD.

Cnossen WR, te Morsche RH, Hoischen A, Gilissen C, Venselaar H, Mehdi S, Bergmann C, Losekoot M, Breuning MH, Peters DJ, Veltman JA, Drenth JP.

Eur J Hum Genet. 2016 Feb;24(2):237-42. doi: 10.1038/ejhg.2015.86. Epub 2015 Apr 29.

44.

Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.

Piazzon N, Bernet F, Guihard L, Leonhard WN, Urfer S, Firsov D, Chehade H, Vogt B, Piergiovanni S, Peters DJ, Bonny O, Constam DB.

J Transl Med. 2015 Mar 30;13:103. doi: 10.1186/s12967-015-0463-7.

45.

Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.

Zhou X, Fan LX, Peters DJ, Trudel M, Bradner JE, Li X.

Hum Mol Genet. 2015 Jul 15;24(14):3982-93. doi: 10.1093/hmg/ddv136. Epub 2015 Apr 15.

46.

Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.

Leonhard WN, Zandbergen M, Veraar K, van den Berg S, van der Weerd L, Breuning M, de Heer E, Peters DJ.

J Am Soc Nephrol. 2015 Jun;26(6):1322-33. doi: 10.1681/ASN.2013080864. Epub 2014 Oct 31.

47.

Translational research in ADPKD: lessons from animal models.

Happé H, Peters DJ.

Nat Rev Nephrol. 2014 Oct;10(10):587-601. doi: 10.1038/nrneph.2014.137. Epub 2014 Aug 19. Review.

PMID:
25137562
48.

Keloids in Rubinstein-Taybi syndrome: a clinical study.

van de Kar AL, Houge G, Shaw AC, de Jong D, van Belzen MJ, Peters DJ, Hennekam RC.

Br J Dermatol. 2014 Sep;171(3):615-21. doi: 10.1111/bjd.13124. Epub 2014 Aug 21. Review.

PMID:
25132000
49.

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium.

Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15.

50.

American income inequality across economic and geographic space, 1970-2010.

Peters DJ.

Soc Sci Res. 2013 Nov;42(6):1490-504. doi: 10.1016/j.ssresearch.2013.06.009. Epub 2013 Jun 26.

PMID:
24090847

Supplemental Content

Loading ...
Support Center